Medtide Inc

Medtide Inc. is a contract research, development, and manufacturing organization providing early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development, along with commercial manufacturing services. The company focuses on oral and/or injectable glucagon-like peptide-1 (GLP-1) molecule products, and its R&D technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. It serves customers in China, the United States, Japan, Europe, South Korea, and Australia. Formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd, it changed its name to Medtide Inc. in February 2023, was incorporated in 2020, and is headquartered in Hangzhou, China.